Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I7EU
|
||||
Former ID |
DNC004298
|
||||
Drug Name |
SB-208651
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Terminated | [545786] | ||
Structure |
Download2D MOL |
||||
Formula |
C28H29N5O4
|
||||
Canonical SMILES |
CN(C1=CC=C(C=C1)C(=N)N)C(=O)C2=CC3=C(CN(C(=O)C(N3)CC(=O<br />)O)CCC4=CC=CC=C4)C=C2
|
||||
InChI |
1S/C28H29N5O4/c1-32(22-11-9-19(10-12-22)26(29)30)27(36)20-7-8-21-17-33(14-13-18-5-3-2-4-6-18)28(37)24(16-25(34)35)31-23(21)15-20/h2-12,15,24,31H,13-14,16-17H2,1H3,(H3,29,30)(H,34,35)
|
||||
InChIKey |
WCZAIWWFRSMLCO-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | ||
Reactome | Platelet degranulation | ||||
Elastic fibre formation | |||||
PECAM1 interactions | |||||
Molecules associated with elastic fibres | |||||
Integrin cell surface interactions | |||||
Syndecan interactions | |||||
ECM proteoglycans | |||||
Integrin alphaIIb beta3 signaling | |||||
GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
p130Cas linkage to MAPK signaling for integrins | |||||
VEGFA-VEGFR2 Pathway | |||||
MAP2K and MAPK activation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.